LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 61

Search options

  1. Article ; Online: Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment.

    Huang, Yuling / Li, Xin / Yang, Lina

    Stem cell research & therapy

    2022  Volume 13, Issue 1, Page(s) 410

    Abstract: ... extracellular vesicles derived from MSCs (MSC-sEVs) in treating COVID-19 were summarized. Then, the molecular ... some therapeutic regimens are available for treatment of COVID-19 pneumonia, including antiviral therapy, immunity ... therapy, anticoagulant therapy, and others. Among them, injection of mesenchymal stem cells (MSCs) is ...

    Abstract Since December 2019, the coronavirus (COVID-19) pandemic has imposed huge burdens to the whole world, seriously affecting global economic growth, and threatening people's lives and health. At present, some therapeutic regimens are available for treatment of COVID-19 pneumonia, including antiviral therapy, immunity therapy, anticoagulant therapy, and others. Among them, injection of mesenchymal stem cells (MSCs) is currently a promising therapy. The preclinical studies and clinical trials using MSCs and small extracellular vesicles derived from MSCs (MSC-sEVs) in treating COVID-19 were summarized. Then, the molecular mechanism, feasibility, and safety of treating COVID-19 with MSCs and MSC-sEVs were also discussed.
    MeSH term(s) COVID-19/drug therapy ; COVID-19/therapy ; Coronavirus Infections/therapy ; Extracellular Vesicles ; Humans ; Mesenchymal Stem Cell Transplantation ; Mesenchymal Stem Cells
    Language English
    Publishing date 2022-08-12
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2548671-8
    ISSN 1757-6512 ; 1757-6512
    ISSN (online) 1757-6512
    ISSN 1757-6512
    DOI 10.1186/s13287-022-03034-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment.

    O'Driscoll, Lorraine

    Drug discovery today

    2020  Volume 25, Issue 7, Page(s) 1124–1125

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections/immunology ; Coronavirus Infections/therapy ; Cytokine Release Syndrome/etiology ; Extracellular Vesicles/physiology ; Humans ; Mesenchymal Stem Cell Transplantation/methods ; Mesenchymal Stem Cells/physiology ; Pandemics ; Pneumonia, Viral/immunology ; Pneumonia, Viral/therapy ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-05-06
    Publishing country England
    Document type Editorial
    ZDB-ID 1324988-5
    ISSN 1878-5832 ; 1359-6446
    ISSN (online) 1878-5832
    ISSN 1359-6446
    DOI 10.1016/j.drudis.2020.04.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4725: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicle Infusion for the Treatment of Respiratory Failure From COVID-19: A Randomized, Placebo-Controlled Dosing Clinical Trial.

    Lightner, Amy L / Sengupta, Vikram / Qian, Sascha / Ransom, John T / Suzuki, Sam / Park, David J / Melson, Timothy I / Williams, Brian P / Walsh, James J / Awili, Mustafa

    Chest

    2023  Volume 164, Issue 6, Page(s) 1444–1453

    Abstract: Background: Bone marrow mesenchymal stem cell (BM-MSC)-derived extracellular vesicles (ExoFlo ... the safety and efficacy of ExoFlo as treatment for moderate to severe ARDS in patients with severe COVID-19 ... Research question: Do two doses of ExoFlo safely reduce mortality in COVID-19-associated moderate ...

    Abstract Background: Bone marrow mesenchymal stem cell (BM-MSC)-derived extracellular vesicles (ExoFlo) convey the immunomodulatory and regenerative properties of intact BM-MSCs. This study aimed to determine the safety and efficacy of ExoFlo as treatment for moderate to severe ARDS in patients with severe COVID-19.
    Research question: Do two doses of ExoFlo safely reduce mortality in COVID-19-associated moderate to severe ARDS compared with placebo?
    Study design and methods: A prospective phase 2 multicenter double-anonymized randomized placebo-controlled dosing trial was conducted at five sites across the United States with infusions of placebo, 10 mL of ExoFlo, or 15 mL of ExoFlo on days 1 and 4. Patients (N = 102) with COVID-19-associated moderate to severe ARDS were enrolled and randomized to treatment. Adverse events were documented throughout the study. The primary outcome measure was all-cause 60-day mortality rate. Secondary outcomes included time to death (overall mortality); the incidence of treatment-emergent serious adverse events; proportion of discharged patients at 7, 30, and 60 days; time to hospital discharge; and ventilation-free days.
    Results: No treatment-related adverse events were reported. Mortality (60-day) in the intention-to-treat population was reduced with 15 mL ExoFlo mixed with 85 mL normal saline (ExoFlo-15) compared with placebo (not significant, χ
    Interpretation: The 15 mL dose of ExoFlo was found to be safe in patients with severe or critical COVID-19-associated respiratory failure. In participants aged 18 to 65 years, the risk reduction in 60-day mortality was further improved from subjects of all ages in the intention-to-treat population after two doses of 15 mL of ExoFlo compared with placebo.
    Clinical trial registration: ClinicalTrials.gov; No.: NCT04493242; URL: www.
    Clinicaltrials: gov.
    MeSH term(s) Humans ; COVID-19/complications ; COVID-19/therapy ; Prospective Studies ; Treatment Outcome ; Respiratory Insufficiency ; Respiratory Distress Syndrome/therapy ; Extracellular Vesicles ; Mesenchymal Stem Cells ; Double-Blind Method
    Language English
    Publishing date 2023-06-23
    Publishing country United States
    Document type Randomized Controlled Trial ; Multicenter Study ; Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1032552-9
    ISSN 1931-3543 ; 0012-3692
    ISSN (online) 1931-3543
    ISSN 0012-3692
    DOI 10.1016/j.chest.2023.06.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui III Zs.45: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 349: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Mesenchymal Stem Cell-Derived Extracellular Vesicles: Promising Treatment for COVID-19 Pandemic.

    Azapira, Negar / Pourjafar, Sarina / Habibi, Azam / Tayebi, Lobat / Keshtkar, Somayeh / Kaviani, Maryam

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation

    2021  

    Abstract: ... derived extracellular vesicles as a new, safe, and effective therapeutic approach in the treatment ... Mesenchymal stromal cell-derived extracellular vesicles contain large amounts of proteins, messenger RNA, and microRNAs ... the pathogenesis of COVID-19 is not completely understood, and finding an effective new drug is still inconclusive ...

    Abstract The pandemic of severe acute respiratory syndrome coronavirus-2 infection has prompted the urgent need for novel therapeutic approaches, especially for patients in critically severe conditions. To date, the pathogenesis of COVID-19 is not completely understood, and finding an effective new drug is still inconclusive. Mesenchymal stromal cell-derived extracellular vesicles contain large amounts of proteins, messenger RNA, and microRNAs that act as vehicles that transfer the cargo between cells. These nanotherapeutic materials exert anti-inflammatory effects on the immune system, which are necessary for subsidence of acute inflammation and promotion of tissue repair and regeneration. Therefore, the consideration of mesenchymal stromal cell-derived extracellular vesicles as a new, safe, and effective therapeutic approach in the treatment of COVID-19 pneumonia is suggested.
    Language English
    Publishing date 2021-02-23
    Publishing country Turkey
    Document type Journal Article ; Review
    ZDB-ID 2396778-X
    ISSN 2146-8427 ; 1304-0855
    ISSN (online) 2146-8427
    ISSN 1304-0855
    DOI 10.6002/ect.2020.0296
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6632: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment

    Yuling Huang / Xin Li / Lina Yang

    Stem Cell Research & Therapy, Vol 13, Iss 1, Pp 1-

    2022  Volume 12

    Abstract: ... and small extracellular vesicles derived from MSCs (MSC-sEVs) in treating COVID-19 were summarized ... At present, some therapeutic regimens are available for treatment of COVID-19 pneumonia, including antiviral ... of mesenchymal stem cells (MSCs) is currently a promising therapy. The preclinical studies and clinical trials using MSCs ...

    Abstract Abstract Since December 2019, the coronavirus (COVID-19) pandemic has imposed huge burdens to the whole world, seriously affecting global economic growth, and threatening people’s lives and health. At present, some therapeutic regimens are available for treatment of COVID-19 pneumonia, including antiviral therapy, immunity therapy, anticoagulant therapy, and others. Among them, injection of mesenchymal stem cells (MSCs) is currently a promising therapy. The preclinical studies and clinical trials using MSCs and small extracellular vesicles derived from MSCs (MSC-sEVs) in treating COVID-19 were summarized. Then, the molecular mechanism, feasibility, and safety of treating COVID-19 with MSCs and MSC-sEVs were also discussed.
    Keywords Mesenchymal stem cells ; Small extracellular vesicles ; COVID-19 ; Molecular mechanism ; Medicine (General) ; R5-920 ; Biochemistry ; QD415-436
    Language English
    Publishing date 2022-08-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Extracellular Vesicles From Mesenchymal Stem Cells as a Covid-19 Treatment

    O'Driscoll, Lorraine

    2020  

    Keywords COVID-19 ; Coronavirus ; Extracellular vesicles ; Mesenchymal stem cells ; Cytokine storm ; SARS-Cov-2 ; Cancer ; Extracellular vesicles (EVs) ; exosomes ; covid19
    Language English
    Publishing country ie
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment

    O’Driscoll, Lorraine

    Drug Discovery Today

    2020  Volume 25, Issue 7, Page(s) 1124–1125

    Keywords Pharmacology ; Drug Discovery ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 1324988-5
    ISSN 1878-5832 ; 1359-6446
    ISSN (online) 1878-5832
    ISSN 1359-6446
    DOI 10.1016/j.drudis.2020.04.022
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4725: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Extracellular Vesicles: The Invisible Heroes and Villains of COVID-19 Central Neuropathology.

    Chang, Haiqing / Chen, Erya / Hu, Yi / Wu, Lining / Deng, Liyun / Ye-Lehmann, Shixin / Mao, Xiaobo / Zhu, Tao / Liu, Jin / Chen, Chan

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

    2023  Volume 11, Issue 10, Page(s) e2305554

    Abstract: ... stem cell (MSCs) secreted EVs are widely applied and evaluated in patients with COVID-19 ... of COVID-19 provides a comprehensive framework for developing, treating, and preventing central ... Acknowledging the neurological symptoms of COVID-19 and the long-lasting neurological damage even ...

    Abstract Acknowledging the neurological symptoms of COVID-19 and the long-lasting neurological damage even after the epidemic ends are common, necessitating ongoing vigilance. Initial investigations suggest that extracellular vesicles (EVs), which assist in the evasion of the host's immune response and achieve immune evasion in SARS-CoV-2 systemic spreading, contribute to the virus's attack on the central nervous system (CNS). The pro-inflammatory, pro-coagulant, and immunomodulatory properties of EVs contents may directly drive neuroinflammation and cerebral thrombosis in COVID-19. Additionally, EVs have attracted attention as potential candidates for targeted therapy in COVID-19 due to their innate homing properties, low immunogenicity, and ability to cross the blood-brain barrier (BBB) freely. Mesenchymal stromal/stem cell (MSCs) secreted EVs are widely applied and evaluated in patients with COVID-19 for their therapeutic effect, considering the limited antiviral treatment. This review summarizes the involvement of EVs in COVID-19 neuropathology as carriers of SARS-CoV-2 or other pathogenic contents, as predictors of COVID-19 neuropathology by transporting brain-derived substances, and as therapeutic agents by delivering biotherapeutic substances or drugs. Understanding the diverse roles of EVs in the neuropathological aspects of COVID-19 provides a comprehensive framework for developing, treating, and preventing central neuropathology and the severe consequences associated with the disease.
    MeSH term(s) Humans ; COVID-19 ; SARS-CoV-2 ; Brain ; Blood-Brain Barrier ; Extracellular Vesicles
    Language English
    Publishing date 2023-12-24
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 2808093-2
    ISSN 2198-3844 ; 2198-3844
    ISSN (online) 2198-3844
    ISSN 2198-3844
    DOI 10.1002/advs.202305554
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Extracellular Vesicles as a Translational Approach for the Treatment of COVID-19 Disease: An Updated Overview.

    Serretiello, Enrica / Ballini, Andrea / Smimmo, Annafrancesca / Acunzo, Marina / Raimo, Mariarosaria / Cantore, Stefania / Di Domenico, Marina

    Viruses

    2023  Volume 15, Issue 10

    Abstract: ... stromal/stem cells (MSCs) and MSC-derived EVs in COVID-19 treatment, such as the use of translational ... to better direct the discovery of future diagnostical tools and new exosome-derived COVID-19 biomarkers ... escape from neutralizing antibodies. Extracellular vesicles (EVs) are phospholipid bilayer-delimited ...

    Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global pandemic in the years 2020-2022. With a high prevalence, an easy route of transmission, and a long incubation time, SARS-CoV-2 spread quickly and affected public health and socioeconomic conditions. Several points need to be elucidated about its mechanisms of infection, in particular, its capability to evade the immune system and escape from neutralizing antibodies. Extracellular vesicles (EVs) are phospholipid bilayer-delimited particles that are involved in cell-to-cell communication; they contain biological information such as miRNAs, proteins, nucleic acids, and viral components. Abundantly released from biological fluids, their dimensions are highly variable, which are used to divide them into exosomes (40 to 150 nm), microvesicles (40 to 10,000 nm), and apoptotic bodies (100-5000 nm). EVs are involved in many physiological and pathological processes. In this article, we report the latest evidence about EVs' roles in viral infections, focusing on the dual role of exosomes in promoting and inhibiting SARS-CoV-2 infection. The involvement of mesenchymal stromal/stem cells (MSCs) and MSC-derived EVs in COVID-19 treatment, such as the use of translational exosomes as a diagnostical/therapeutic approach, is also investigated. These elucidations could be useful to better direct the discovery of future diagnostical tools and new exosome-derived COVID-19 biomarkers, which can help achieve optimal therapeutic interventions and implement future vaccine strategies.
    MeSH term(s) Humans ; COVID-19/therapy ; COVID-19/metabolism ; SARS-CoV-2 ; COVID-19 Drug Treatment ; Extracellular Vesicles/metabolism ; Exosomes/metabolism
    Language English
    Publishing date 2023-09-22
    Publishing country Switzerland
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v15101976
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top